Gerald Raverot

Has grant

Professor

Hospices Civils de Lyon

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Gerald Raverot is a Professor at Hospices civils de Lyon, France. His research focuses on the management of aggressive pituitary tumors and carcinomas, with recent publications addressing the clinical practice guidelines, systemic treatment effects, and diagnostic advancements in this area. He is also involved in studying the clinicopathological characteristics of recurrent gonadotroph tumors and the implications of somatic mutations in prolactinomas.

Recent Grants

Grant: Close

Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH) (PITUIGENE)

Open Date: 2013-01-01

Close Date: 2018-12-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Philippe Chanson

Université Paris-Saclay

FRANCE

View details

Gudmundur Johannsson

University of Gothenburg

SWEDEN

View details

Olaf M Dekkers

Leiden University Medical Center

NETHERLANDS

View details

Arja Pasternack

University of Helsinki

FINLAND

View details

Antoine Tabarin

FRANCE

View details

Mirela-Diana Ilie

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gerald Raverot

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice

Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis

From hyperplasia to carcinoma: a molecular driven adrenal disease

Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas

Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors

A promising new direct immunoassay for urinary free cortisol determination

Evaluation of the analytic performance and macroprolactin sensitivity of a new prolactin immunoassay

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine

Evidence for somatic mutation screening on aggressive prolactinomas

Letter to the Editor From Salle et al.: “A Prospective Multicenter Observational Study of Surgical Versus non-surgical Management for Pituitary Apoplexy”

Evidence of Persistent Mild Hypercortisolism in Patients Medically Treated for Cushing Disease: the Haircush Study

The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal

Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?—that is the question

Current Advances in Papillary Craniopharyngioma: State-Of-The-Art Therapies and Overview of the Literature

Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas

Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review

Inhibition of activin signalling reduces the growth of LβT2 gonadotroph pituitary tumours in mouse

IGSF1 mutations are the most frequent genetic aetiology of thyrotropin deficiency

Clinical Biology of the Pituitary Adenoma

Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients

Collaborators (6)

Philippe Chanson

Gudmundur Johannsson

Olaf M Dekkers

Arja Pasternack

Antoine Tabarin

Mirela-Diana Ilie

Make your next move.